Skip to main content

Drug Interactions between lindane topical and Mazanor

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

mazindol lindane topical

Applies to: Mazanor (mazindol) and lindane topical

MONITOR: Lindane penetrates human skin and has the potential to cause central nervous system toxicity. Seizures have been reported after excessive use or oral ingestion of lindane. There may be a theoretical risk of increased seizure potential when lindane is used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.

MANAGEMENT: Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.g., head trauma, brain tumor, metabolic disorders, alcohol and drug withdrawal, CNS infections). Lindane should be used according to recommended dosage and directions for application.

References

  1. Telch J, Jarvis DA (1982) "Acute intoxication with lindane (gamma benzene hexachloride)." Can Med Assoc J, 126, p. 662-3
  2. Munk ZM, Nantel A (1977) "Acute lindane poisoning with development of muscle necrosis." Can Med Assoc J, 117, p. 1050-4
  3. Tenenbein M (1991) "Seizures after lindane therapy." J Am Geriatr Soc, 39, p. 394-5
  4. Pramanik AK, Hansen RC (1979) "Transcutaneous gamma benzene hexachloride absorption and toxicity in infants and children." Arch Dermatol, 115, p. 1224-5
  5. Matsuoka LY (1981) "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol, 5, p. 98-9
  6. Solomon BA, Haut SR, Carr EM, Shalita AR (1995) "Neurotoxic reaction to lindane in an HIV-seropositive patient: an old medication's new problem." J Fam Pract, 40, p. 291-6
  7. "Product Information. Kwell (lindane)." Reed and Carnrick, Jersey City, NJ.
  8. Ramchander V, Cameron ES, Reid HF (1991) "Lindane toxicity in an infant." West Indian Med J, 40, p. 41-3
  9. Cox R, Krupnick J, Bush N, Houpt A (2000) "Seizures caused by concomitant use of lindane and dextroamphetamine in a child with attention deficit hyperactivity disorder." J Miss State Med Assoc, 41, p. 690-2
View all 9 references

Switch to consumer interaction data

Drug and food interactions

Moderate

mazindol food

Applies to: Mazanor (mazindol)

GENERALLY AVOID: Alcohol may potentiate the central nervous system and cardiovascular effects of centrally-acting appetite suppressants. In one study, concurrent administration of methamphetamine (30 mg intravenously) and ethanol (1 gm/kg orally over 30 minutes) increased heart rate by 24 beats/minute compared to methamphetamine alone. This increases cardiac work and myocardial oxygen consumption, which may lead to more adverse cardiovascular effects than either agent alone. Subjective effects of ethanol were diminished in the eight study subjects, but those of methamphetamine were not affected. The pharmacokinetics of methamphetamine were also unaffected except for a decrease in the apparent volume of distribution at steady state.

MANAGEMENT: Concomitant use of centrally-acting appetite suppressants and alcohol should be avoided if possible, especially in patients with a history of cardiovascular disease. Patients should be counselled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References

  1. Mendelson J, Jones RT, Upton R, Jacob P 3rd (1995) "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther, 57, p. 559-68
  2. (2001) "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn
  3. (2012) "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer